The Week in Review: September 29 – October 6, 2017

Friday, October 6, 2017 News Recap: Liver Cancer Two studies on liver cancer in the news last week highlighted the global prevalence and causes of this terrible disease.  The first showed a direct correlation between excess weight and cancer occurrence (including liver cancer) – Cancers linked to excess weight make up 40% of all US diagnoses, study finds, while the second focussed on the global incidence of primary liver cancer. Hepatitis B virus wa...

Viekira Pak safe for patients with HCV, Child-Pugh A cirrhosis

Patients with hepatitis C and Child-Pugh A cirrhosis had similar rates of treatment-related adverse events and lower rates of hepatic decompensation after treatment with Viekira Pak (Holkira Pak in Canada) compared with untreated patients, according to recently published data. However, those with a history of advanced cirrhosis were more likely to experience treatment-related adverse events. “Importantly, many of the events consistent with hepatic decompe

Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study

Do you have cataracts? Did you ever take interferon? Hmmmm!!! Hepatitis C virus (HCV) infection is associated with increased systemic oxidative stress, which leads to cardiovascular events, diabetes, and chronic kidney disease. Similarly, cataract is also associated with increased oxidative stress. The association between HCV infection and increased risk of cataract remains unclear. In this study, we observed a positive association between pegylated in

Patient Input Requested for Merck Interferon-Free Combo

HepCBC is seeking individual patient input for our submission to the federal government for an INTERFERON-FREE, ONE PILL/DAY drug combo, shown to be effective for genotypes 1, 3, 4, and 6, Merck Pharmaceutical's elbasvir + grazoprevir (± ribavirin). The treatment's success (96% - 100% SVR12) has been confirmed in trials including people considered 'hard to treat' including those who had failed previous treatment (including simeprevir, boceprevir, and telap

REQUEST: Patient input for BC Pharmacare RE: HOLKIRA PAK™

BC PharmaCare has issued a call for Patient Input into whether they should cover AbbVie's new hepatitis C treatment, HOLKIRA PAK™ (ombitasvir, paritaprevir, ritonavir, and dasabuvir [±ribavirin]).HepCBC is going to make a submission to BC PharmaCare, and URGENTLY requests input from those who have, or have ever had hepatitis C (and their caregivers). Our submission is only as good as the input we get from people like you!You would have to answer a few ques

HEALTH CANADA APPROVES AbbVie Interferon-Free HCV Combo

What a Christmas Present! On December 23, 2014, Health Canada approved AbbVie's new interferon-free hepatitis C combo! HOLKIRA™ PAK (known in the USA as VIEKIRA™ PAK) has an overall 97% success rate for genotype 1 patients in research trials. All patients, even those with compensated cirrhosis, take it for only 12 weeks EXCEPT genotype 1a cirrhotic patients who have had a previous null response to pegylated interferon (pegIFN) and ribavirin, who must take

Simeprevir (GALEXOS) now covered in Quebec as well!

Simeprevir (GALEXOS) is also now covered on the Quebec formulary, according to CATIE, the Canadian AIDS Treatment Information Exchange. However, it is only available to those who have already failed conventional treatment with interferon and ribavirin. It is available only to genotype 1 patients who do not have the Q80K mutation and not co-infected with HIV. MUST MEET ALL THESE QUALIFICATIONS TO GET REIMBURSED FOR SIMEPREVIR: -- to be used in association w